Anthropic Targets Scientific Discovery with Claude for Life Sciences and Expanded Research Funding

Anthropic has launched Claude for Life Sciences, a specialized initiative designed to transform its AI models from simple task assistants into comprehensive research partners. The program aims to support scientists across every stage of development, from early-stage biological discovery to clinical translation and commercialization. Led by Jonah Cool, Head of Life Sciences Partnerships and Deployment, and Eric Kauderer-Abrams, Head of Biology and Life Sciences Research, the initiative is built on the philosophy of teaching the AI to behave like a trained biologist rather than a general-purpose chatbot.

Outperforming Human Baselines and Linking Workflows

At the core of this scientific push is improved model performance. On the Protocol QA benchmark, which tests comprehension of laboratory procedures, the Claude Sonnet 4.5 model achieved a score of 0.83, outperforming the human baseline score of 0.79 and its predecessor, Sonnet 4, which scored 0.74. The model also demonstrated marked improvements on BixBench, a key evaluation framework for bioinformatics tasks. To integrate these capabilities directly into active laboratories, Anthropic introduced Model Context Protocol connectors. These integrations link the AI to widely used scientific platforms, including Benchling for experimental records, BioRender for scientific illustrations, PubMed for literature retrieval, Wiley Scholar Gateway for peer-reviewed journals, Synapse.org for collaborative data sharing, and 10x Genomics for single-cell analysis. Newer integrations have also expanded to Medidata, ClinicalTrials.gov, ChEMBL, bioRxiv/medRxiv, and ToolUniverse.

Beyond standard queries, the platform employs Claude Code and agentic skills. These are specialized folders of instructions and scripts that the AI loads dynamically to execute complex workflows. For example, the single-cell-qc skill automates the quality control and filtering of single-cell RNA sequencing data following scverse industry standards. One researcher noted that an issue requiring three months of continuous laboratory work by multiple staff members was solved by Claude in a single response, demonstrating the speed-up potential of these agentic tools.

Pharma Adoption and Commercial Momentum

Major pharmaceutical companies are already deploying the platform to streamline long drug development timelines. Novo Nordisk utilized the system to condense the preparation of clinical study documentation from a period of over ten weeks down to just ten minutes. Other global firms, including Sanofi, AbbVie, and Genmab, are utilizing the platform for regulatory compliance, drug discovery, and cancer therapy development. To assist with enterprise-wide deployments, Anthropic has partnered with consulting firms such as Deloitte, KPMG, PwC, and Slalom, making the platform available via Claude.com, AWS Marketplace, and Google Cloud Marketplace.

This scientific expansion coincides with explosive financial growth for Anthropic. The company expanded its enterprise customer base from under 1,000 to more than 300,000, pushing its annualized revenue past $9 billion in late 2025, with projections reaching $18 billion for 2026. This momentum has been supported by the launch of Claude for Healthcare with HIPAA-ready tools, alongside newer model families including Opus 4.5, Opus 4.6, and the Claude 4 generation. This rapid expansion places Anthropic in direct competition with other specialized scientific AI solutions, such as Emerit Science's sovereign AI agent, Charlie.

Funding Scientific Breakthroughs Globally

To support non-commercial scientific research, Anthropic operates the AI for Science Program, which provides free API credits to academic and nonprofit researchers working on high-impact biology, chemistry, and life sciences projects. Under this program, selected research teams can receive up to $20,000 in API credits for a six-month period. Applications are evaluated on the first Monday of each month based on scientific merit, technical feasibility, and the credentials of the team.

To maintain regulatory compliance and safety, the program enforces strict eligibility criteria. Individual applicants must be at least 18 years old, and participating institutions must clear all internal consents. Furthermore, the program excludes applicants residing in Belarus, China, Cuba, Iran, Myanmar, North Korea, Russia, Sudan, Syria, Crimea, and the Donetsk or Luhansk regions. All participants remain bound by Anthropic's standard usage and safety policies, which are monitored by the company's trust and safety team.

Whether these automated pipelines can maintain rigorous safety and compliance standards as they scale will be the critical test for the pharmaceutical industry's next generation of drugs.